Core Insights - Traws Pharma announced positive topline results from studies on tivoxavir marboxil, showing its efficacy in treating H5N1 bird flu in ferrets, consistent with previous murine model results [1][2][3] - The company is conducting further studies in non-human primates, with data expected in Q1 2025, and plans to approach the FDA for accelerated approval under the "Animal Rule" [2][3] Company Overview - Traws Pharma is a clinical-stage biopharmaceutical company focused on developing oral small molecule therapies for respiratory viral diseases, including bird flu and seasonal influenza [6] - The company is developing two drug candidates: tivoxavir marboxil for bird flu and seasonal influenza, and ratutrelvir for COVID-19 treatment [6] Product Details - Tivoxavir marboxil is designed to inhibit the influenza protein CAP-dependent endonuclease (CEN) and has shown potent in vitro activity against various influenza strains, including H5N1 [5] - The antiviral market for bird flu and seasonal influenza is estimated to represent a multi-billion dollar opportunity, driven by global health organizations and government tenders [5]
Traws Pharma Reports Positive Results from An Accepted Bird Flu Model for Anti-Viral Candidate, Tivoxavir Marboxil